Today the FDA has approved Eli Lilly’s Alzheimer’s drug donanemab expanding the limited treatment options available for those living with Alzheimer’s disease. At Loretto, we celebrate this news today and the hope it provides for those living with Alzheimer’s and dementia.
Breaking News: The FDA has granted approval of Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We celebrate Kisunla’s approval as more options mean greater opportunity for more time. This is the third approval of an Alzheimer’s treatment that changes the underlying course of the disease. bit.ly/3XIyyvf